JonesResearch initiated coverage of Gritstone with a Buy rating and $10 price target. The analyst sees Gritstone as a “highly underappreciated story,” especially given the post-pandemic pullback of COVID-related names. The company’s vaccine candidates in oncology and infectious disease are differentiated from mRNA vaccines in both immunogenicity and durability, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GRTS:
- Gritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023
- Gritstone price target raised to $7 from $6 at Piper Sandler
- Gritstone gets BARDA contract up to $433M to evaluate Covid-19 candidates
- Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
- Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
